Morgan Stanley Issues Positive Forecast for MiniMed Group (NASDAQ:MMED) Stock Price

MiniMed Group (NASDAQ:MMED) had its price target raised by research analysts at Morgan Stanley from $19.00 to $21.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price points to a potential downside of 10.81% from the stock’s previous close.

A number of other analysts have also recently weighed in on the company. Mizuho upped their price target on MiniMed Group from $21.00 to $26.00 and gave the company an “outperform” rating in a research report on Wednesday. Benchmark reissued a “buy” rating on shares of MiniMed Group in a report on Thursday, June 4th. Weiss Ratings upgraded shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. Citigroup increased their target price on shares of MiniMed Group from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Bank of America boosted their price target on shares of MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.77.

MiniMed Group Stock Performance

NASDAQ MMED traded down $0.21 during trading on Thursday, reaching $23.55. 137,369 shares of the company traded hands, compared to its average volume of 1,107,661. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $24.43. The firm has a market capitalization of $6.62 billion and a P/E ratio of -34.79. The stock has a 50 day moving average price of $17.84.

MiniMed Group (NASDAQ:MMED) last issued its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. Equities research analysts forecast that MiniMed Group will post 0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MiniMed Group

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in MiniMed Group by 7,527.5% in the 2nd quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock valued at $29,848,000 after acquiring an additional 1,970,314 shares in the last quarter. J. Goldman & Co LP bought a new stake in shares of MiniMed Group during the second quarter valued at approximately $12,412,000. Readystate Asset Management LP acquired a new stake in shares of MiniMed Group in the second quarter valued at approximately $4,400,000. Bank of America Corp DE raised its position in MiniMed Group by 377.0% in the 2nd quarter. Bank of America Corp DE now owns 238,819 shares of the company’s stock worth $3,570,000 after purchasing an additional 188,756 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in MiniMed Group during the 2nd quarter worth $1,745,000.

Trending Headlines about MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 sales growth of approximately 17%, while earnings per share exceeded analyst expectations. The results helped support renewed optimism about the company’s operating momentum. MiniMed Group Q1 2027 Deep Dive: EPS Beats, Revenue Up 17%
• Positive Sentiment: Several firms raised their price targets following the quarterly report. UBS lifted its target to $28 from $25, Bank of America raised its target to $28 from $24, and BTIG increased its target to $28 from $25; all maintained or initiated bullish “buy” ratings. MiniMed Group Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Mizuho, Wells Fargo and Citigroup each raised their targets to $26, with ratings of “outperform,” “overweight” and “buy,” respectively. The revisions indicate broader analyst confidence after the sales performance. Analysts Boost Forecasts Following Q1 Sales Results
• Neutral Sentiment: The overall broker consensus target is $21.62, below the reference price of $23.76, although the latest individual target increases are substantially higher. This divergence suggests that older estimates may not yet reflect the latest earnings update. MiniMed Group Receives Consensus Target Price from Brokerages

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.